Nasdaq
$3.08▲ 0.31%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $4.6MShares out 1.5M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
3- 8.31After-hours26.09.01 05:598-KKey event#●●●
DNA X, Inc.
DNA X, Inc. received notification on August 28, 2026, that it has regained compliance with Nasdaq's stockholders' equity requirement of at least $2.5 million. The company remains subject to all Nasdaq listing rules until November 18, 2026, and will be under mandatory panel monitoring for one year until August 28, 2027.…more
$3.08+0.31%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.27Pre-market26.08.27 20:328-KKey event
DNA X, Inc.
DNA X, Inc. has approved a substitute cash grant for its board members and CEO in lieu of restricted stock units (RSUs) due to a lack of available shares under its 2019 Equity Incentive Plan. The grant, valued at $60,000 as of August 21, 2026, will be paid out upon the company's 2027 annual meeting or a change in control.…more
$3.08+0.31%vs prev closeView filingShare - 8.19After-hours26.08.20 05:3210-QEarnings
DNA X, Inc.
DNA X, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, reporting 1,488,268 shares of common stock outstanding as of August 18, 2026. The company continues to operate its cryptocurrency trading platform and develop related technologies, while facing ongoing challenges regarding Nasdaq listing compliance and the availability of liquidity to fund operations.…more
$3.08+0.31%vs prev closeView filingShare
2 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 8.19After-hours26.08.20 05:21#●●●
DNA X Expects Trading Platform Revenue by Late 2026
DNA X announced that it expects revenue from its trading platform to begin towards the end of the third quarter or the beginning of the fourth quarter of 2026. This guidance outlines the company's projected timeline for monetization rather than immediate financial results.…more
$3.08+0.31%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 8.19After-hours26.08.20 05:18
●●●●●●●● ●●●●● ●●●●●●
DNA X reported a quarterly loss of $(0.91) per share, significantly narrowing from the $(14.15) loss recorded in the same period last year. While the loss has decreased, the company remains unprofitable, requiring further monitoring of its path to profitability.…more
$3.08+0.31%vs prev closeShareBenzinga - 8.19After-hours26.08.20 05:15
●●●●●●●● ●●●●● ●●●●●●
DNA X reported no revenue for the second quarter and continued to incur operating losses. The company has raised capital through convertible debt and preferred stock offerings to fund its AI trading platform business.…more
$3.08+0.31%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report